Conditions: Hypertension
Keywords: Hypertension Angiotensin Receptor Blocker Calcium Channel Blocker Angiotensin Converting Enzyme Inhibitor Hydrochlorothiazide Stage I and II Hypertension Type II Diabetes
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 192
Healthy volunteers: no

Brief summary:
This study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients with Type II diabetes and high blood pressure. The medication being tested has been approved by the FDA for the treatment of high blood pressure.

Detailed description:

Arms:
arm 1: Blood pressure (BP) measurements were taken every three weeks for 12 weeks. In accordance with their BP results, participants either stayed on their current medication or were started on the next higher regimen at the 3, 6, or 9 week visits. All participants began at 20 mg olmesartan, once daily for 3 weeks. The next higher regimen was olmesartan 40 mg, followed by olmesartan 40 mg + 12.5 mg hydrochlorothiazide, followed by olmesartan 40 mg + 25 mg of hydrochlorothiazide.

Interventions: intervention 1: olmesartan medoxomil intervention 2: Olmesartan medoxomil plus Hydrochlorothiazide
Intervention descriptions: intervention 1: Olmesartan medoxomil tablets, once daily intervention 2: Olmesartan medoxomil and hydrochlorothiazide combination tablets, once daily, if necessary

Protocol document: